By 2025, the Inflatable Penile Implant segment held a 72.77% share of the penile implants market, reflecting its established role in treatment settings where patient expectations around functional control and a more natural post-implant experience strongly influence device selection. its position is maintained through the preference for solutions that more closely align with lifestyle and intimacy needs, especially in cases where procedural decision-making prioritizes long-term satisfaction and device performance. This keeps Inflatable Penile Implant demand anchored at the higher end of the penile implants market despite the greater simplicity of alternative options.

The Non-inflatable/Malleable Penile Implant segment is emerging as the fastest-growing area of the penile implants market because its practical advantages fit well with situations where procedural simplicity and ease of use matter most. Growth is being aided by demand for implant options that can reduce handling complexity for both surgeons and patients, making them increasingly attractive in appropriate clinical scenarios. Relative to inflatable systems, the straightforward design of Non-inflatable/Malleable Penile Implant products is the clearest factor accelerating their uptake.

End-use Segment Analysis: Hospital (Largest Segment) vs Ambulatory Surgery Centers (ASCs) (Fastest-Growing Segment)

Hospitals accounted for the largest share of the penile implants market in 2025, aided by their central role in managing implant procedures that require coordinated surgical care, specialist availability, and broader perioperative support. Their leadership is reinforced by the concentration of urology expertise and operating infrastructure needed for patient evaluation, implantation, and post-procedure management within a single setting. This makes hospitals the primary end-use environment in the penile implants market, particularly for cases where institutional capabilities remain a key part of treatment delivery.

Ambulatory Surgery Centers (ASCs) are the fastest-growing end-use segment in the penile implants market as procedural migration toward more efficient outpatient settings gains traction. Their momentum is tied to the appeal of streamlined surgical workflows and settings designed for lower-complexity, scheduled procedures, which can improve operational efficiency without relying on the broader hospital environment. Compared with hospitals, ASCs are benefiting most from the shift toward specialized care delivery models that better suit selected penile implant procedures.